Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01799824 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
A Phase 2 study of Primary Axillary Hyperhidrosis, sponsored by Anterios.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT01799824: Completed Phase 2 study of Primary Axillary Hyperhidrosis, sponsored by Anterios.
NCT01799824 is a Phase 2 study of Primary Axillary Hyperhidrosis that has completed, run by Anterios. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01799824, a Phase 2 study of Primary Axillary Hyperhidrosis, has completed, sponsored by Anterios.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL ANT-1403
Study Locations (9)
Florida
- - Miami
- - Pinellas Park
- - West Palm Beach
Kentucky
- - Louisville
New Jersey
- - East Windsor
New York
- - Rochester
North Carolina
- - Raleigh
Pennsylvania
- - Yardley
Virginia
- - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT01799824 record still lists
NCT01799824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Primary Axillary Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01799824 lists 9 locations in 7 states (Florida, Kentucky, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01799824 about?
NCT01799824 is a clinical study titled "Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis". The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
What is the current status of trial NCT01799824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2013-02. Estimated completion is 2013-07.
What conditions does trial NCT01799824 study?
This clinical trial studies the following conditions: Primary Axillary Hyperhidrosis.
What interventions are being tested in trial NCT01799824?
The interventions under investigation include: placebo (BIOLOGICAL), ANT-1403 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01799824?
This trial is sponsored by Anterios, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01799824 being conducted?
This trial has 9 study locations across Florida, Kentucky, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01799824's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia